Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis
Open Access
- 25 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (2), 201-204
- https://doi.org/10.1093/jpids/piaa039
Abstract
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved pharmacokinetic targets in children living with HIV aged 4 weeks to <2 years receiving concurrent rifampin to treat TB. NCT01751568.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Mental Health (UM1AI106716, HHSN275201800001I, UM1AI068632, UM1AI068616)
This publication has 6 references indexed in Scilit:
- Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2–12 years on rifampicin for tuberculosisAIDS, 2019
- Treating young children co-infected with tuberculosis and HIVThe Lancet HIV, 2018
- Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical studyThe Lancet HIV, 2018
- Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship*Journal of Antimicrobial Chemotherapy, 2014
- Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of RaltegravirAntimicrobial Agents and Chemotherapy, 2009
- Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009